| Literature DB >> 33975986 |
Jian-Hong Wu1,2, Dong-Ya Wang2, Lu Sheng2, Wei-Qing Qian2, Shu-Jie Xia1,3, Qi Jiang1,3.
Abstract
Mesenchymal stem cells (MSCs) secrete various cytokines with angiogenic and neuroprotective effects. This study aimed to assess the effects of human umbilical cord Wharton's jelly-derived MSCs (hWJ-MSCs) on diabetes-related intracavernosal pressure (ICP) impairment in rats. hWJ-MSCs were isolated from human umbilical cord Wharton's jelly and transplanted into the corpus cavernosum of streptozotocin (STZ)-induced diabetic rats by unilateral injection. The erectile function was evaluated at 4 weeks, as well as the expression levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), endothelial nitric oxide synthase (eNOS), and insulin-like growth factor 1 (IGF1). STZ-induced diabetic rats showed impaired ICP, which was significantly improved by hWJ-MSC treatment. VEGF, eNOS, IGF1, and bFGF expression levels were higher in hWJ-MSC injection sites than those in control ones in STZ-induced diabetic rats. These results suggest that hWJ-MSC transplantation might improve diabetic erectile dysfunction through increased production of paracrine growth factors, highlighting a novel potential therapeutic option for erectile dysfunction.Entities:
Keywords: diabetes; endothelial nitric oxide synthase; erectile dysfunction; mesenchymal stem cells; vascular endothelial growth factor
Mesh:
Substances:
Year: 2022 PMID: 33975986 PMCID: PMC8887109 DOI: 10.4103/aja.aja_33_21
Source DB: PubMed Journal: Asian J Androl ISSN: 1008-682X Impact factor: 3.285
Primers used for quantitative reverse transcription-polymerase chain reaction
|
|
| |
|---|---|---|
|
| TGACGGACAGACAGACAGACACC | AGAGCCCAGAAGTTGGACGAA |
|
| GGCTGCTGGCTTCTAAGTGT | CCAACTGGAGTATTTCCGTGA |
|
| ACAGGCATCACCAGGAAGAAG | CTCAGAGCCATACAGGATAGTCG |
|
| GGCACTCTGCTTGCTCACCTT | ACGAACTGAAGAGCGTCCACC |
VEGF: vascular endothelial growth factor; bFGF: basic fibroblast growth factor; eNOS: endothelial nitric oxide synthase; IGF1: insulin-like growth factor 1
Serum glucose levels and body weights
|
|
|
|
|
|
|---|---|---|---|---|
| Body weight (g) | ||||
| Initial | 214.5±9.85 | 218.0±7.52 | 217.0±6.75 | 0.25 |
| 12 weeks | 401.4±20.86 | 190.7±18.95 | 188.6±21.34 | <0.0001 |
| Blood glucose level (mmol l−1) | ||||
| 72 h | 6.76±0.26 | 23.85±1.62 | 24.59±2.32 | <0.0001 |
| 8 weeks | 6.75±0.31 | 24.26±2.11 | 25.02±2.18 | <0.0001 |
| 12 weeks | 7.01±0.28 | 22.46±2.31 | 23.64±3.22 | <0.0001 |
Each group included 10 animals, and values are shown as mean±s.d. MSCs: mesenchymal stem cells; NDM: normal rat; DM: diabetes rat; MSC: diabetes rat injected with mesenchymal stem cells; s.d.: standard deviation
Intracavernosal pressure levels and intracavernosal pressure increase/mean arterial pressure were measured before treatment and 4 weeks after treatment
|
|
|
|
|
|
|---|---|---|---|---|
| ICP (cmH2O) | ||||
| Pretreatment | 96.6±8.7 | 30.5±7.9 | 31.3±7.5 | 0.41 |
| Posttreatment | 95.2±10.6 | 29.7±8.5 | 65.4±14.5 | <0.01 |
| ICP/MAP | 0.76±0.21 | 0.26±0.14 | 0.61±0.18 | <0.01 |
Each group included 10 animals, and values are shown as mean±s.d. MSCs: mesenchymal stem cells; NDM: normal rat; DM: diabetes rat; MSC: diabetes rat injected with mesenchymal stem cells; s.d.: standard deviation; ICP: intracavernosal pressure; MAP: mean arterial pressure